Back to News
investment

Invesco Health Care Fund Q4 2025 Commentary

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Health care outperformed all sectors in Q4 2025, driven by strong gains in pharmaceuticals, biotechnology, and life sciences tools, despite broader equity growth fueled by AI optimism and lower interest rates. Stock selection in health care equipment, facilities, and life sciences tools hurt relative performance, with overweights in facilities and tech further dragging returns. Pharmaceuticals and biotech led sector gains, while distributors and life sciences tools also contributed positively, offsetting weaker areas like health care equipment. The fund underweighted pharmaceuticals and life sciences tools, missing out on their strong performance, while overweights in lower-performing facilities and tech weighed on results. Managers expect health care to match broader equity market performance in 2026, signaling cautious optimism amid shifting economic conditions.
AI Audio Summary
0:00 / 0:00
Click to play
Nov 30, 2025, 05_47_17 PM.png
Quantum News · Media Library

Invesco US3.33K FollowersFollow5ShareSavePlay(13min)CommentsSummaryStock selection in health care equipment, life sciences tools & services, and facilities detracted from relative performance.Overweights in facilities and health care technology and underweights in life sciences tools & services and pharmaceuticals also detracted.The health care sector outperformed all other sectors during the fourth quarter of 2025.Pharmaceuticals, biotechnology, distributors and life sciences tools & services were notable positive drivers of sector performance.We expect health care to generally perform in line with the overall equity market as we move into 2026. Jonathan Kitchen/DigitalVision via Getty Images Manager perspective and outlook Equities generally moved higher during the fourth quarter of 2025, seemingly fueled by continued optimism around artificial intelligence (AI) capital spending and lower interest rates. The health care sector outperformed This article was written byInvesco US3.33K FollowersFollowInvesco is an independent investment management firm dedicated to delivering an investment experience that helps people get more out of life.Be the first to know! Sign up for Invesco US Blog and get expert investment views as they post.Disclosure for all Invesco US articles: Before investing, carefully read the prospectus and/or summary prospectus and carefully consider the investment objectives, risks, charges and expenses. The information provided is for educational purposes only and does not constitute a recommendation of the suitability of any investment strategy for a particular investor. Invesco does not provide tax advice. The tax information contained herein is general and is not exhaustive by nature. Federal and state tax laws are complex and constantly changing. Investors should always consult their own legal or tax professional for information concerning their individual situation. The opinions expressed are those of the authors, are based on current market conditions and are subject to change without notice. These opinions may differ from those of other Invesco investment professionals. NOT FDIC INSURED MAY LOSE VALUE NO BANK GUARANTEE All data provided by Invesco unless otherwise noted. Invesco Distributors, Inc. is the US distributor for Invesco Ltd.’s retail products and collective trust funds. Invesco Advisers, Inc. and other affiliated investment advisers mentioned provide investment advisory services and do not sell securities.

Invesco Unit Investment Trusts are distributed by the sponsor, Invesco Capital Markets, Inc., and broker-dealers including Invesco Distributors, Inc. PowerShares® is a registered trademark of Invesco PowerShares Capital Management LLC (Invesco PowerShares). Each entity is an indirect, wholly owned subsidiary of Invesco Ltd. ©2015 Invesco Ltd. All rights reserved.

Read Original

Tags

drug-discovery
government-funding

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.